



US007863249B2

(12) **United States Patent**
Chiu et al.

(10) **Patent No.:** **US 7,863,249 B2**
(45) **Date of Patent:** ***Jan. 4, 2011**

(54) **MACROLIDE POLYMORPHS,
COMPOSITIONS COMPRISING SUCH
POLYMORPHS, AND METHODS OF USE AND
MANUFACTURE THEREOF**

5,583,115 A 12/1996 McAlpine et al.
5,767,096 A 6/1998 Hochlowski et al.
7,378,508 B2 * 5/2008 Chiu et al. 536/7.1

(Continued)

(75) Inventors: **Yu-Hung Chiu**, San Diego, CA (US);
Tessie Mary Che, San Diego, CA (US);
Alex Romero, San Diego, CA (US);
Yoshi Ichikawa, San Diego, CA (US);
Youe-Kong Shue, Carlsbad, CA (US)

FOREIGN PATENT DOCUMENTS

WO WO 96/35702 11/1996
WO WO 2004/014295 2/2004
WO WO 2005/112990 12/2005
WO WO 2006/085838 A 8/2006

(73) Assignee: **Optimer Pharmaceuticals, Inc.**, San
Diego, CA (US)

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 391 days.

This patent is subject to a terminal dis-
claimer.

Remington: The Science and Practice of Pharmacy, published 2000
by Lippincott Williams and Wilkins, pp. 802-803.*
Babakhani et al., "Narrow spectrum activity and low fecal protein
binding of Opt-80 and its major hydrolysis metabolite (OP-1118)",
Program and Abstract of the 47th Interscience Conference on Anti-
microbial Agents and Chemotherapy Chicago, IL, p. 212 (2007),
XP008103008.

(Continued)

(21) Appl. No.: **12/101,552**

(22) Filed: **Apr. 11, 2008**

(65) **Prior Publication Data**

US 2008/0194497 A1 Aug. 14, 2008

Related U.S. Application Data

(63) Continuation of application No. 11/831,886, filed on
Jul. 31, 2007, now Pat. No. 7,378,508.

(60) Provisional application No. 60/881,950, filed on Jan.
22, 2007.

(51) **Int. Cl.**

A61K 31/7032 (2006.01)

A61K 31/7048 (2006.01)

C07H 17/08 (2006.01)

(52) **U.S. Cl.** **514/28; 536/7.1**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,978,211 A 8/1976 Coronelli et al.
4,918,174 A 4/1990 McAlpine et al.

Primary Examiner—Eric S Olson

(74) *Attorney, Agent, or Firm*—Morgan Lewis & Bockius
LLP

(57)

ABSTRACT

The invention relates to novel forms of compounds displaying
broad spectrum antibiotic activity, especially crystalline
polymorphic forms and amorphous forms of such com-
pounds, compositions comprising such crystalline polymor-
phic forms and amorphous forms of such compounds, pro-
cesses for manufacture and use thereof. The compounds and
compositions of the invention are useful in the pharmaceuti-
cal industry, for example, in the treatment or prevention of
diseases or disorders associated with the use of antibiotics,
chemotherapies, or antiviral therapies, including, but not lim-
ited to, colitis, for example, pseudo-membranous colitis; anti-
biotic associated diarrhea; and infections due to *Clostridium*
difficile ("C. difficile"), *Clostridium perfringens* ("C. perfrin-
gens"), *Staphylococcus* species, for example, methicillin-re-
sistant *Staphylococcus*, or *Enterococcus* including Vancomy-
cin-resistant enterococci.

17 Claims, 3 Drawing Sheets

